IGF-1
Last reviewed September 26, 2026
IGF-1 is the primary mediator of growth hormone's effects. Research examines its role in anabolic signaling, tissue growth, and the pathways downstream of the growth-hormone axis.
Mechanism of action
Research describes IGF-1 as acting at its own receptor to trigger signaling cascades associated with protein synthesis and cellular proliferation.
- Downstream MediatorStudied as the molecule through which much of growth hormone's activity is actually expressed.
- Anabolic SignalingExplored for activation of pathways associated with protein synthesis and tissue growth.
- Route studied
- Subcutaneous
- Research status
- Approved analog
Recombinant human IGF-1 has been developed as the pharmaceutical agents mecasermin and mecasermin rinfabate, which are the subject of clinical drug reviews, while much of the remaining research on IGF-1 is in animal and cell models.
What the research covers
What research examines
- Anabolic signaling and protein synthesis pathways
- Growth hormone axis downstream signaling
- Bone composition and remodeling in mouse models
- Organ-specific growth in fetal sheep
- Intraventricular hemorrhage prevention in preterm rabbit pups (with IGFBP-3)
- Metabolic effects of altered IGF-1 bioavailability in animal models
Reported effects in studies
- Human safety data for research-grade IGF-1 are limited
- Adverse events are not summarized in the cited preclinical studies
- IGF-1 signaling has been studied as a driver of breast cancer cell invasion and migration via PI3K/Akt pathways
- Sex-specific differences in bone and metabolic responses reported in PAPPA2-deficient mouse models
What research protocols have used
Research protocols have used 20–100 mcg per administration, once daily (morning), in 4-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorCited research
- Recombinant IGF-1 Induces Sex-Specific Changes in Bone Composition and Remodeling in Adult Mice with Pappa2 Deficiency.
International journal of molecular sciences · 2021 · PubMed 33919940
- Sheep recombinant IGF-1 promotes organ-specific growth in fetal sheep.
Frontiers in physiology · 2022 · PubMed 36091374
- Evaluation of recombinant human IGF-1/IGFBP-3 on intraventricular hemorrhage prevention and survival in the preterm rabbit pup model.
Scientific reports · 2023 · PubMed 37963901
- Mecasermin.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2008 · Review · PubMed 18481900
- Mecasermin rinfabate.
Drugs of today (Barcelona, Spain : 1998) · 2007 · Review · PubMed 17380212
Questions about IGF-1
IGF-1 (insulin-like growth factor 1) is described in research as the primary mediator of growth hormone's effects. Studies examine its role in anabolic signaling, tissue growth, and the pathways that sit downstream of the growth-hormone axis. Recombinant forms of IGF-1 have been produced in expression systems such as Pichia pastoris, and pharmaceutical versions known as mecasermin and mecasermin rinfabate have been the subject of published clinical drug reviews.
Research describes IGF-1 as acting at its own receptor to trigger signaling cascades associated with protein synthesis and cellular proliferation. It is studied as the molecule through which much of growth hormone's activity is actually expressed. Cell studies have linked IGF-1 receptor activity to PI3K/Akt signaling, a pathway associated with growth and survival, which is one reason IGF-1 is also examined in cancer biology research.
Animal work has examined recombinant IGF-1 effects on bone composition and remodeling in adult mice with Pappa2 deficiency, organ-specific growth in fetal sheep, and, combined with IGFBP-3, intraventricular hemorrhage prevention and survival in a preterm rabbit pup model. Other research has explored how altered IGF-1 bioavailability relates to sex-specific metabolic changes. These are research findings in models and do not establish outcomes in humans.
Human safety data for research-grade IGF-1 are limited, and adverse events are not summarized in the cited preclinical studies. Because IGF-1 promotes cellular proliferation, cell research has examined its role in breast cancer cell invasion and migration through PI3K/Akt signaling. Animal studies have also reported sex-specific differences in bone and metabolic responses, indicating that effects may vary with biological context.
Research protocols have used 20 to 100 mcg per administration, once daily in the morning, in 4-week blocks followed by 4 weeks off, with a subcutaneous route described. These figures reflect what protocols have reported and are not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference. CoreX products are sold for laboratory research use only.
Ask about IGF-1
Our research assistant answers questions about the science, the studied ranges, and our products. It can be wrong, and it does not give medical advice.
IGF-1 at CoreX
Every batch is independently tested for identity and purity, and the certificate of analysis is tied to the lot number on your label.
Foundation
$139.00









